-DOCSTART- -X- O
Against -X- _ O
a -X- _ O
backdrop -X- _ O
of -X- _ O
seasonal -X- _ O
influenza -X- _ O
virus -X- _ O
epidemics -X- _ O
, -X- _ O
emerging -X- _ O
avian -X- _ O
influenza -X- _ O
viruses -X- _ O
( -X- _ O
AIVs -X- _ O
) -X- _ O
occasionally -X- _ O
jump -X- _ O
from -X- _ O
birds -X- _ O
to -X- _ O
humans -X- _ O
, -X- _ O
posing -X- _ O
a -X- _ O
public -X- _ O
health -X- _ O
risk -X- _ O
, -X- _ O
especially -X- _ O
with -X- _ O
the -X- _ O
recent -X- _ O
sharp -X- _ O
increase -X- _ O
in -X- _ O
H7N9 -X- _ O
infections. -X- _ O
Evaluations -X- _ O
of -X- _ O
cross-reactive -X- _ B-Intervention
T-cell -X- _ I-Intervention
immunity -X- _ I-Intervention
to -X- _ I-Intervention
seasonal -X- _ I-Intervention
influenza -X- _ I-Intervention
viruses -X- _ I-Intervention
and -X- _ I-Intervention
human-infecting -X- _ I-Intervention
AIVs -X- _ I-Intervention
have -X- _ O
been -X- _ O
reported -X- _ O
previously. -X- _ O
However -X- _ O
, -X- _ O
the -X- _ O
roles -X- _ O
of -X- _ O
influenza -X- _ O
A -X- _ O
virus-derived -X- _ O
epitopes -X- _ O
in -X- _ O
the -X- _ O
cross-reactive -X- _ B-Patient
T-cell -X- _ I-Patient
responses -X- _ I-Patient
and -X- _ O
heterosubtypic -X- _ O
protections -X- _ O
are -X- _ O
not -X- _ O
well -X- _ O
understood -X- _ O
; -X- _ O
understanding -X- _ O
those -X- _ O
roles -X- _ O
is -X- _ O
important -X- _ O
for -X- _ O
preventing -X- _ O
and -X- _ O
controlling -X- _ O
new -X- _ O
emerging -X- _ O
AIVs. -X- _ O
Here -X- _ O
, -X- _ O
among -X- _ O
the -X- _ O
members -X- _ O
of -X- _ O
a -X- _ O
healthy -X- _ O
population -X- _ O
presumed -X- _ O
to -X- _ O
have -X- _ O
previously -X- _ O
been -X- _ O
infected -X- _ B-Outcome
by -X- _ I-Outcome
pandemic -X- _ I-Outcome
H1N1 -X- _ I-Outcome
( -X- _ I-Outcome
pH1N1 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
we -X- _ I-Outcome
found -X- _ I-Outcome
that -X- _ I-Outcome
pH1N1-specific -X- _ I-Outcome
T -X- _ I-Outcome
cells -X- _ I-Outcome
showed -X- _ I-Outcome
cross- -X- _ I-Outcome
but -X- _ I-Outcome
biased -X- _ I-Outcome
reactivity -X- _ I-Outcome
to -X- _ I-Outcome
human-infecting -X- _ I-Outcome
AIVs -X- _ I-Outcome
, -X- _ I-Outcome
i.e. -X- _ I-Outcome
, -X- _ I-Outcome
H5N1 -X- _ I-Outcome
, -X- _ I-Outcome
H6N1 -X- _ I-Outcome
, -X- _ I-Outcome
H7N9 -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
H9N2 -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
correlates -X- _ I-Outcome
with -X- _ I-Outcome
distinct -X- _ I-Outcome
protections. -X- _ I-Outcome
Through -X- _ O
a -X- _ O
T-cell -X- _ O
epitope-based -X- _ O
phylogenetic -X- _ O
analysis -X- _ O
, -X- _ O
the -X- _ O
cellular -X- _ O
immunogenic -X- _ O
clustering -X- _ O
expanded -X- _ O
the -X- _ O
relevant -X- _ O
conclusions -X- _ O
to -X- _ O
a -X- _ O
broader -X- _ O
range -X- _ O
of -X- _ O
virus -X- _ O
strains. -X- _ O
We -X- _ O
defined -X- _ O
the -X- _ O
potential -X- _ O
key -X- _ O
conserved -X- _ O
epitopes -X- _ O
required -X- _ O
for -X- _ O
cross-protection -X- _ O
and -X- _ O
revealed -X- _ O
the -X- _ O
molecular -X- _ O
basis -X- _ O
for -X- _ O
the -X- _ O
immunogenic -X- _ O
variations. -X- _ O
Our -X- _ O
study -X- _ O
elucidated -X- _ O
an -X- _ O
overall -X- _ O
profile -X- _ O
of -X- _ O
cross-reactivity -X- _ O
to -X- _ O
AIVs -X- _ O
and -X- _ O
provided -X- _ O
useful -X- _ O
recommendations -X- _ O
for -X- _ O
broad-spectrum -X- _ O
vaccine -X- _ O
development -X- _ O
. -X- _ O

